A complete White Glove Insights™ Report — the clinical artifact delivered to every patient within 24 hours. Structured, source-linked, and co-signed by two fellowship-trained physicians.
This report uses a fictional patient with synthetic data. All physician names, hospital references, and clinical values are illustrative.
15 pages · 3 risk models · 75+ extracted variables · Every data point source-linked
Combined aortic valve replacement and coronary artery bypass grafting (AVR-CABG)
Before any analysis begins, the report assembles every relevant clinical detail into a structured summary. Diagnoses, medical history, current medications, and the surgical recommendation you received — all verified against the source documents.
Every value on this page links to the exact page and document it was extracted from. Nothing is assumed.
We don’t take the referring diagnosis at face value. Every diagnostic finding is verified against the original imaging, lab, and catheterization data — because errors in the starting data propagate into surgical decisions.
In 18% of cases, our independent review identifies a diagnostic discrepancy that changes the risk calculation or alters the recommended approach.
We calculate STS-PROM, EuroSCORE II, and AATS risk scores using 75+ variables extracted directly from your records. These are patient-specific scores — not generic risk categories. When the models disagree, we explain why.
Mr. Mitchell's STS-PROM of 5.7% places him in the intermediate-risk category. Combined with moderate LV dysfunction and 3-vessel CAD, this makes the AVR-CABG decision nuanced.
Combined open-heart procedure. Bioprosthetic aortic valve replacement with 3-vessel coronary bypass (LIMA-LAD, SVG-LCx, SVG-RCA). Single operation, single recovery.
Complete revascularization in one procedure. Superior long-term outcomes per SYNTAX data. Addresses both pathologies definitively.
Higher short-term morbidity (STS M&M 28.4%). Extended recovery (8–12 weeks). Requires cardiopulmonary bypass.
Transcatheter aortic valve replacement followed by percutaneous coronary intervention 4–6 weeks later. Two procedures, two recoveries, but each minimally invasive.
Each procedure individually lower risk. Faster recovery from each. Avoids sternotomy.
Two separate procedures and recovery periods. PCI unlikely to achieve complete revascularization (3-vessel, SYNTAX 34). Dual antiplatelet + TAVR antithrombotic overlap.
Aggressive medical therapy with close surveillance. Guideline-directed medical therapy for CAD with watchful waiting for aortic stenosis progression.
No procedural risk. Appropriate if patient declines intervention.
Symptomatic severe AS carries ~50% 2-year mortality without intervention. Ongoing angina and HF symptoms. Does not address underlying pathology.
The report doesn’t tell you what to do. It maps every viable treatment pathway, quantifies the trade-offs, and presents the evidence for each. Surgical, interventional, and conservative options — all compared against your specific anatomy and risk profile.
For Mr. Mitchell, three pathways are viable: AVR-CABG (combined), TAVR + staged PCI, and medical management. Each carries different short-term and long-term risk profiles.
We don’t just give opinions — we cite the evidence. Every recommendation is mapped to ACC/AHA, ESC/EACTS, and STS clinical practice guidelines with specific class and level of evidence designations.
Surgical AVR is a Class I recommendation (Level A evidence) for severe symptomatic AS. CABG is Class I for 3-vessel CAD with reduced LVEF. The combination is well-supported.
We match you to surgeons and centers based on procedure-specific volume, publicly reported outcomes, and geographic accessibility. Not advertising. Not referral networks. Data.
For AVR-CABG, center volume matters. Programs performing 200+ AVR-CABG cases annually have mortality rates 40% lower than low-volume programs.
Proceed with combined surgical aortic valve replacement (bioprosthetic) and coronary artery bypass grafting (AVR-CABG) at a high-volume center (≥200 combined cases/year).
Two fellowship-trained physicians — a cardiac surgeon and an interventional cardiologist — independently review the AI analysis and co-sign the final recommendation. This is the ACC/AHA Class I Heart Team standard.
The Heart Team concurs with the recommendation for surgical AVR-CABG, with specific guidance on valve type, graft strategy, and center selection.
Every clinical value in the report is linked to the specific document and page from which it was extracted. You — or your physician — can verify any data point by referencing the source index.
Source-linked provenance is what separates a WhiteGloveMD report from a traditional second opinion. Nothing is assumed. Nothing is unverifiable.
Every White Glove Insights™ Report is generated from your actual medical records — not a template. Delivered in 24 hours. Inaugural pricing from $495.